SAN JOSE, Calif., March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop, Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018, at 4:30 p.m. China Standard Time, 4:30 a.m. Eastern Standard Time, at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS) in Hangzhou, China.

"We are pleased to present at this conference that is expected to bring together over 1,000 Asian investors and strategic partners.  This conference provides us a unique opportunity to provide exposure for our company and technologies to a global audience," said John Roop, Senior Vice President of Engineering of ITUS Corporation.

The China Healthcare Investment & Partnering Symposium is hosted by TPP Healthcare and supported by a leading investment bank B.Riley FBR, in conjunction with the Chinese Pharmaceutical Enterprise Association (CPEA), the leading association of healthcare companies with over 3,000 members. 

For more information on the conference agenda, please access: https://www.meetmax.com/sched/event_47969/~public/conference_home.html.

ITUS Corporation

ITUS, a cancer-focused biotechnology company, is harnessing the body's immune system in the fight against cancer.  Its wholly owned subsidiary, Anixa Diagnostics Corporation, is developing the Cchek™ platform, a series of non-invasive blood tests for the early detection of solid tumor based cancers, which is based on the body's immunological response to the presence of a malignancy.  Its majority owned subsidiary, Certainty Therapeutics, Inc., is developing CAR-T based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer.  ITUS also continually examines emerging technologies in complementary or related fields for further development and commercialization.  Additional information is available at www.ITUScorp.com.

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect ITUS Corporation's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

ITUS Corporation: FOCUSED ON INNOVATION™

View original content with multimedia:http://www.prnewswire.com/news-releases/itus-corporation-to-present-at-the-2018-inaugural-china-healthcare-investment--partnering-symposium-chips-300611240.html

SOURCE ITUS Corporation